ALYREF and prostate carcinoma: Our study revealed that ALYREF was the most significant risk factor for PCa patients, as shown in Additional file 2: Fig. S2D and E. In order to investigate the role of 13 m5C regulators in prostate cancer, we attempted to cluster these samples based on their expression levels using an unsupervised clustering approach.